<p>Geron’s(GERN Quote – Cramer on GERN – Stock Picks) upcoming and widely publicized stem cell trial involving patients with spinal cord injuries was criticized as risky and clinically dubious because the entire rationale for the study is "based on a single experiment in eight rats."</p> <p>More on GERN M&A Flurry Can’t Lift MarketStock Search: Merck and Shering Plough Fail To Spark The MarketsStock Wrap: The Real Story March 93 Stocks I Saw on TVBiotech Stock Mailbag: Geron GambitGeron’s Stem-Cell Research Hype Soaks InvestorsGeron’s a Slow-Go, Not a No-GoU.S. Steel, American Express Gird StocksFour Must-See Charts of the Day: Small-Cap Stocks to WatchCAT Can’t Scratch Indices Market Activity Aastrom Biosciences Incorporated| ASTM UPThe negative view of Geron’s research effort came from a spinal surgeon and stem cell researcher during a conference call for institutional investors held Monday by Summer Street Research Partners, an independent health care research firm…</p>
That All May Walk Again!